GLP-1 RAs, an established treatment option for T2DM, has been confirmed to stimulate insulin secretion and suppress glucagon secretion in a glucose-dependent manner with a low risk of hypoglycemia, indicating its efficacy and satiety [4]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.